Sevoflurane therapy for life-threatening asthma in children

Asthma is a common disease in children and often develops early in life. This multicentre retrospective case series describe the use and effectiveness of sevoflurane inhalation therapy in a series of children with severe asthma in the paediatric intensive care unit (PICU). Seven children ranging from 4 to 13 yr of age admitted to the PICU of two tertiary care hospitals in the Netherlands were included. They all were admitted with the diag-nosis of severe asthma requiring invasive mechanical ventilation and were treated with sevoflurane inhalation therapy. The median (range) Pco(2) level at the start, after 2 h, and at the end of sevoflurane treatment were 14 (5.124.8), 9.8 (5.417.0), and 6.2 (4.511.4) kPa (P0.05) while the median (range) pH was 7.02 (6.977.36), 7.18 (7.047.35), and 7.43 (7.157.47) kPa (P0.01), respectively. The median (range) peak pressure values declined from 30 (2356) to 20.4 (1433) cm H2O (P0.03). No severe adverse effects besides hypotension, with sufficient response to norepinephrine treatment, were seen. Sevoflurane inhalation corrects high levels of Pco(2) and provides clinical improvement in mechanically ventilated children with life-threatening asthma who fail to respond to conventional treatment.